GFP
AZN icon

Gryphon Financial Partners’s AstraZeneca AZN Stock Holding History

Gryphon Financial Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,306
Closed -$608K – 366
2025
Q4 		$608K Buy
3,306
+570
+21% +$100K 0.07% 188
2025
Q3 		$420K Buy
2,736
+311
+13% +$47.1K 0.05% 215
2025
Q2 		$339K Buy
+2,425
New +$340K 0.04% 228
2018
Q3 		– Sell
-354
Closed -$25K – 216
2018
Q2 		$25K Hold
354
– – 0.01% 342
2018
Q1 		$25K Hold
354
– – 0.01% 351
2017
Q4 		$25K Buy
+354
New +$23.9K 0.01% 359

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Gryphon Financial Partners's AZN Position: Q1 2026 in Review

Gryphon Financial Partners sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 3,306 shares — an estimated $608K sold.

Gryphon Financial Partners first reported a position in AZN in Q4 2017 and held it in 6 quarters. The position peaked at $608K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Gryphon Financial Partners reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Gryphon Financial Partners sold 3,306 AstraZeneca shares in Q1 2026, an estimated $608K.
  • Gryphon Financial Partners first reported a position in AstraZeneca in Q4 2017 and held it in 6 quarters.
  • Gryphon Financial Partners's AstraZeneca position peaked at $608K in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Gryphon Financial Partners's 13F filing for Q1 2026, filed 6 May 2026.